BOTHELL, Wash., Feb. 4, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company held its second bi-annual technical seminar in Seoul, South Korea, exclusively focused on early-phase development and manufacturing.
With the theme "Development of Biologics and Speed to IND," the seminar took place on January 23, 2018, and incorporated a variety of topics surrounding early-phase development and manufacturing. Presentations included an overview of AGC Biologics' dedicated early-phase facility in Berkeley, California (USA); a deep dive into the company's proprietary CHEF1® Expression System; an analysis of High-Throughput Technologies and their capabilities in accelerating speed to IND; a discussion of analytical considerations for early-phase projects headed to commercialization; and quality considerations unique to early-phase development. The seminar also featured a discussion on current perspectives on biological therapeutics in Korea, presented by guest speaker Junho Chung, M.D., Ph.D., Professor, Department of Biochemistry and Molecular Biology, Seoul National University School of Medicine & Cancer Research Institute, Seoul National University.
The technical seminar drew more than 200 attendees from small and large biotech organizations, universities, and research centers.
A product of the recent convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, AGC Biologics recently announced its new brand name in early January 2018. Under the AGC Biologics brand name, the company will maintain and grow its global presence with microbial and mammalian capabilities, fulfilling early-phase through late-phase projects, both at small- and large-scale.
"We're extremely pleased with a very successful technical seminar, and enjoyed our time sharing information with our colleagues and partners in Seoul," said Graham Byng, Seminar Chair and Sr. Director of Business Development at AGC Biologics. "A genuine thank you to all who attended the event, and we look forward to a productive year as we continue to strengthen our partnerships in South Korea."
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.
AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1® Expression System for mammalian production. Further information can be found at www.agcbio.com.
AGC Biologics Media Contact Information:
Ms. Kim Yang
Director, Global Marketing and Communications
Office: +1 425.415.5438